T he human immunodeficiency virus (HIV) is an enveloped virus that infects permissive cells by the fusion of viral and cellular membranes, a process initiated by the attachment of HIV particles to cells. Consequently, to complement the current anti-HIV protease and reverse transcriptase drugs, several novel anti-HIV molecules have been developed that target different components implicated in the mechanism of HIV attachment and entry into cells (1) . In this respect, the pentameric HB-19 pseudopeptide, 5[K(CH 2 N)PR]TASP, is an anti-HIV synthetic agent that inhibits HIV infection by binding to the cell-surfaceexpressed nucleolin and results in a block in the attachment of virus particles to cells (2) (3) (4) . Nucleolin is one of the major RNA binding proteins of the nucleolus, which has also been found on the cell surface where it serves as a binding protein for different ligands including HIV (5) (6) (7) . In view of its potent and specific mode of action against various isolates of HIV, HB-19 represents a potential anti-HIV drug.
In the present study, we have mapped potential peripheral targets for the HB-19 pseudopeptide by examining in vivo the gross tissue distribution of the radiolabeled pseudopeptide with whole rat body mapping (8) . The visual imaging of the entire animal by ␤-radio imaging provided a convenient and efficient technique to examine and record simultaneously the uptake of HB-19 in a large number of tissues and compartments. Of particular interest in respect to pathogenesis of HIV infection (9) , our results show a preferential uptake of HB-19 by lymphoid organs. Moreover, the chromatographic characteristics of the bloodstream labeled compound indicated that more than 90% of the label is associated with the intact HB-19. This latter, and the significant, proportion of HB-19 recovered from target organs as late as 24 h post-administration of the labeled pseudopeptide could account for the strong peptidase resistance of HB-19. Furthermore, in accord with our previous in vitro results in cell cultures, nucleolin was recovered from the target tissues of rats systematically injected with the biotin-labeled HB-19, by virtue of this pseudopeptide to form in vivo a stable and an irreversible complex with the surface-expressed nucleolin. , the control peptide 5[R(CH 2 N)PN]-TASP (herein referred to as CP-51), and the corresponding biotin-labeled peptides were as described (2, 7) . For the preparation of the tritium-labeled HB-19, a precursor molecule of HB-19 was synthesized in which the proline residue in the tripeptide K(CH 2 N)PR moiety was replaced by a 3,4-dehydroproline residue before labeling with tritium [ ]-labeled HB-19 was 0.22 TBq͞mmol (6 Ci͞mmol; 1 Ci ϭ 37 GBq). All of the peptides used in this study had a purity Ն90%. After lyophilization, the peptides were dissolved and͞or diluted in PBS (Dulbecco's) and stored at Ϫ80°C. ʈ To whom reprint requests should be addressed. E-mail: arahovan@pasteur.fr.
Materials and Methods Peptide Constructs. The synthesis of 5[K(CH 2 N)PR]-TASP (herein referred to as
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sagittal sections (20 m) of the frozen rat were made at Ϫ30°C with a cryostat (whole-body slicing microtome Leitz 400 with a chest mobile freezer Leitz OM from Leica, Deerfield, IL). Sections adhering to Scotch tape were left in a freezer (Ϫ30°C) for 4 days to ensure complete drying. The quantitative determination of the radioactivity in whole-body sections was carried out by ␤-imager 2200 (Biospace, Paris; refs. 8, 10, and 11 8 . At different time points after peptide administration (2-120 min), 250 l of blood sample were withdrawn, and the entire urinary bladder content was collected at the last selected point. The blood and urine samples were centrifuged (2500 ϫ g for 15 min at 4°C) and the supernatants stored at Ϫ80°C. Aliquots (100 l) of the biological samples were acidified by addition of 10 l of 1N HCl, kept at 4°C for 10 min, and then centrifuged (12,000 ϫ g for 10 min at 4°C), before adsorption on Sep-Pak Plus tC2 cartridges (Waters). Peptide fractions were eluted from the Sep-Pak with 0.1% trifluoroacetic acid (TFA) in acetonitrile (Merck), and after evaporation of the solvent phase they were applied to a Kromasil column (150 ϫ 4.6 mm; HPLC RP-C 18 chromatography; AIT, St. Germain en Laye, France). Following a 15-min isocratic run of 0.1% TFA in water, the elution was performed with a linear gradient of 0.1% TFA in water-0.1% TFA in acetonitrile for 15 min at a flow rate of 1 ml͞min. Fractions were collected every 60 s and analyzed for radioactivity by using a liquid scintillation counter.
SIPHAR (Simed, Créteil, France), a computer program designed for nonlinear regression of pharmacokinetic data, was used to fit plasma concentration. The data used correspond to the plasma or urine concentration of nonmetabolized HB-19. Pharmacokinetic parameters were evaluated as described (12) , using a two-compartmental model. The area under the plasma concentration curve (AUC) was determined by using trapezoidal rule and extrapolated to infinity. Clearance was calculated from the dose divided by AUC. Elimination rate constants (k␣ and k␤) were evaluated from the decay of the plasma concentration curve after i.v. administration of HB-19. Volume of distribution was determined by using the ratio clearance:k␤.
Chromatographic Characterization of the Radioactive Pseudopeptide.
The chromatographic characteristics of the labeled pseudopeptide in the plasma, urine, and in different tissues were assessed by RP-HPLC (8) . At selected times (4, 8 , and 24 h) after i.v. injection of 20 g (50 Ci) of [ 3 H]-labeled HB-19, urine was collected and the rats were anesthetized and killed by cardiac blood puncture. Tissues were quickly removed weighed and homogenized mechanically at 4°C in 5-10 volumes of 0.1 M chlorhydric acid in a Polytron system (Polytron, type PT 10͞35, Kinematica, Lucerne, Switzerland). Homogenates were centrifuged at 15,000 ϫ g for 30 min at 4°C. To determine total radioactivity, aliquots of the supernatant solution were dried on filter and counted in a liquid scintillation counter. The biological samples were submitted to Sep-Pak Plus tC2 extraction conditions as described above. Chromatography using the HPLC procedure described above was then applied to each extracted sample. The radioactivity content of samples before and after chromatographic separations was determined by using a beta counter (MR300 from Kontron, Zurich).
Characterization of Tissue Nucleolin Complexed with the Biotin-
Labeled HB-19. These experimental conditions were previously optimized for the recovery of the cell-surface-expressed nucleolin complexed with the biotin-labeled HB-19 in vitro (7, 13, 14) . Anesthetized rats were injected intravenously with 1 mg of the biotin-labeled HB-19 or the biotin-labeled control peptide CP-51. After 45 min, the anesthetized rats were killed (cardiac blood puncture) and the tissues quickly removed and frozen at Ϫ80°C. Frozen tissues were homogenized mechanically (Polytron) in low-salt buffer (10 mM Hepes, pH 7.6͞10 mM KCl͞2 mM magnesium acetate͞7 mM 2-mercaptoethanol and the protease inhibitor mixture) containing unlabeled HB-19 (50 M). This suspension was left for 15 min at 4°C before addition of Nonidet P-40 at a final concentration of 0.5%. After 15 min, each suspension was sonicated for 10 s and centrifuged at 5000 ϫ g for 20 min. The potential complexes formed between tissue proteins and the biotin-labeled HB-19 or the biotin-labeled CP-51 were isolated by purification of the extracts (50 mg), using 100 l of avidin-agarose (ImmunoPure Immobilized Avidin from Pierce) in PBS containing EDTA (1 mM). After 2 h of incubation at 4°C, the samples were washed extensively with PBS-EDTA. The purified peptide-complexed proteins were denatured by heating in the electrophoresis sample buffer containing SDS and analyzed by SDS͞PAGE electrophoresis (14) . The presence of nucleolin was then revealed by immunoblotting using rabbit polyclonal antibody against hamster (CHO cells) nucleolin as described (14) . Similarly purified peptide-complexed proteins were eluted by 1 M NaCl and dialyzed against PBS containing 1 mM EDTA and protease inhibitor mixture. The eluted samples were then analyzed by dot-immunoblotting (15) using rabbit polyclonal antibody against hamster nucleolin. (6) . Internalized HB-19 accumulates in the cytoplasm of cells, but it does not enter the nuclei. Therefore, HB-19 does not cross the nuclear membrane, and consequently its effect is exerted differentially through the cell-surfaceexpressed nucleolin. Because nucleolar nucleolin could control cell growth through the biosynthesis of ribosomes (16) , the lack of translocation of HB-19 to the nucleus and nucleolus might account for its lack of toxicity in cultured cells.
Results and Discussion
For a preliminary evaluation of a potential acute toxicity of HB-19 in animals, male rats (body weight of 100 g) were injected intravenously through the jugular vein with 0.03, 0.3, and 3 mg͞kg of HB-19 (n ϭ 2 rats per dose). No apparent change was noted in the behavior and physiological characteristics of rats injected with HB-19 during the 48 h period of observation, at which time the animals were killed for gross anatomic examination. Fig. 1  A-C) . The dynamic profile of HB-19 uptake in rats revealed that the radioactivity is rapidly distributed and differentially retained in the liver, spleen, kidney, and bones including vertebrae as early as 5 min postinjection and remained stably accumulated at least 1 h after systemic injection. Interestingly, the radioactivity persisted within different organs as late as 24 h postinjection of [ 3 H]-labeled HB-19. In a less exposed sagittal section at 1 h postinjection (Fig. 1D) , it was possible to clearly distinguish the significant radioactive signal (in red) within the kidney concentrated toward the inner medullar collecting ducts, which is consistent with the fact that the clearance of the bloodstream HB-19 occurred through the urine (see below). The -imager magnification of the spleen (Fig. 1F ) and a section from the long bone femur (Fig. 1E) illustrated the uptake and accumulation of [ (Fig. 2A) . Compared with this background anatomic space, the relative high tissue accumulation of radioactivity in the spleen at 5 min postdose decreased 2-3 times by 1 h, but remained stably retained as late as 24 h after injection of 20 g of HB-19. In addition, under these experimental conditions, the level of radioactivity was also rapidly and stably accumulated within the inner bone. On the other hand, an almost comparable level of labeling was observed in the spleen and bone of rats injected with 200 g of HB-19, thus suggesting that saturation of the peptide uptake sites was not achieved in both tissues under these experimental conditions. In contrast, the 5-fold-higher radioactivity in the liver of rats injected with 200 g of HB-19 compared with that injected with 20 g at 5 min . Direct quantification of sagittal whole-body sections was assessed by using the ␤-radio imager. The number of ␤-particles emitted per area was counted for 50 h and expressed as counts per mm 2 per 1 h. Assessment of quantitative regional differences was performed with computer-assisted image analysis using the ␤-VISION program. Bars represent means Ϯ SD of triplicate determinations from the same structure and two whole-body sections.
postinjection could be accounted for by the suggestion that the liver is an efficient organ of metabolism for the HB-19 pseudopeptide. Similarly, within the kidney of rats injected with 200 g of HB-19, the level of the radioactivity was higher in the medullar area compared with the cortical area, which is consistent with an accelerated process of the peptide excretion. At both concentrations of HB-19, the labeling in the kidney at 24 h postinjection was almost completely excluded, thus indicating that most of the peptide had been eliminated (Fig. 2B) . Fig.  3A ; the circulating tritiated HB-19 distribution phase could be estimated at 25 min (Fig. 3A) . Sep-Pak and RP-HPLC fractionation of plasma peptide extracts revealed that in the bloodstream at least 90% of the radioactivity was recovered in a peak corresponding to the intact native form of HB-19 at any time after injection of [ 3 H]-labeled HB-19 (Figs. 3A and 4 A and B). All these results indicated that the intact HB-19 disappears from the blood compartment with an apparent distribution half-life of about 15 min because of its biodistribution in other compartments, including target tissues. Hence, despite the fact that at 60 min 90% of HB-19 was cleared from circulation, a significant amount of radiolabeled HB-19 is accumulated within the lymphoid tissues even at 24 h postinjection (Fig. 2 A) . The HB-19 urinary elimination was investigated by measuring radioactivity excreted in two rats injected with 20 g of [ (Fig. 3B) . Interestingly in the urine, the intact HB-19 represented only a small proportion of the total radioactivity recovered at the different time intervals. Indeed, more than 98% of the urine radioactivity appeared to be recovered as HB-19 metabolites that are eliminated through Sep-Pak extraction step and͞or intermediate peptide products as revealed by the RP-HPLC modified elution profile (Fig. 4C) . In contrast to the urine, significant levels of the intact HB-19 were still recovered from the target tissues (liver, spleen, kidney, and thymus) even at 24 h postinjection, which is consistent with its long half-life in the target tissues (Table 1 and Fig. 4 D-F) . Our results show that HB-19 is stable in the rat bloodstream. This and the observation that at least 30% of HB-19 persists undegraded in the target lymphoid organs at 24 h postinjection suggest that HB-19 may exert a long-term effect on HIV infection in vivo. Such a resistance is consistent with our previous reports on the stability of HB-19 in vitro, in fetal calf or human sera (13) . 29 ml͞min͞kg) is close to the filtration clearance in rat, suggesting that other elimination processes do not occur significantly in the fate of HB-19. This is in agreement with the chromatographic experiments on blood. Volume of distribution is 410 ml͞kg, indicating that HB-19 is concentrated in a moderate manner in peripheral tissues.
The urinary excretion of HB-19 is rather slow because only 0.15% of the drug is eliminated during the first 4 h and that elimination still occurs between 8 and 24 h after administration. It seems that a very deep compartment could exist. By comparing plasma AUC (area under the plasma concentration curve) and renal elimination, the renal clearance could be estimated.
The calculated value (0.1 ml͞min͞kg) is very low, suggesting that HB-19 could be subjected to tubular reabsorption or metabolism into the urine. This effect is consistent with the high ratio of metabolites:HB-19 calculated from the urine data. Such a case has already been shown for a 4-aa peptide, NacSDKP (17) .
Recovery of the Molecular Target for HB-19 from Different Tissues in
Vivo. Rats were injected with the biotin-labeled HB-19 or its corresponding control pseudopeptide CP-51. Tissue extracts were then prepared and the biotin-labeled peptide complexes were purified by affinity chromatography using avidin-agarose. The presence of nucleolin copurified with the biotin-labeled HB-19 was revealed by immunoblotting with the antinucleolin antibody in dot-blot analysis of crude tissue extracts or after PAGE (Fig. 5) . The results revealed that nucleolin was recovered from the liver, spleen, thymus, and bone marrow, but not from the kidney of rats injected with the biotin-labeled HB-19. We had previously demonstrated that in different types of cell cultures, HB-19 binds specifically to the cell-surface-expressed nucleolin, forming a stable complex that constitutes a specific event for the HB-19 action. Similarly, the recovery of the HB-19-complexed nucleolin from different rat tissues should also be the consequence of a specific event because nucleolin was not recovered when rats were injected with the biotin-labeled control pseudopeptide CP-51. It is of interest to note that the ␤-imager mapping of sagittal sections of rats injected with [ 3 H]-labeled HB-19 showed that the peptide is highly accumulated in renal inner medulla (Fig. 1) , whereas no nucleolin was recovered from the kidney tissue extracts of the rat injected with the biotinlabeled HB-19 (Fig. 5) . Therefore, the presence of [ 3 H]-labeled HB-19 within kidney reflects predominantly the clearance process of the pseudopeptide from the bloodstream. In contrast to the kidney, the liver that functions as an organ of metabolism for various drugs appears as an important target tissue for HB-19 action and͞or metabolism through nucleolin binding sites.
It is of interest to note that the K d value of HB-19 to bind partially purified preparations of nucleolin is in the order of 9.6 ϫ 10 9 M Ϫ1 (14) . Furthermore, under experimental conditions required for the inhibition of HIV particle attachment to cells, HB-19 forms a stable and irreversible complex in vitro with the cell-surface-expressed nucleolin in various types of cells (6, 7, 13, 14) . This complex is then internalized by an active process into the cytoplasm where it becomes accumulated without entering the nuclei (A.G.H., B.K., and J.P.B., unpublished results). The recovery of the HB-19-nucleolin complex from lymphoid tissues of the rat injected with the biotin-labeled HB-19 suggests that surface nucleolin is the molecular target of HB-19 in vivo. The preferential uptake of HB-19 in lymphoid organs could then be accounted for by the presence of actively proliferating cells including lymphocytes in such organs, because surface expression of nucleolin is highly regulated by growth stimulation of cells. Indeed, surface-nucleolin expression is drastically down-regulated in growth-arrested cells, whereas in growth-activated cells its expression is markedly induced, both at the level of mRNA and protein expression at the cell surface (6, 18) . The increased levels of surface nucleolin in growth-activated cells (6) by binding to HB-19 could contribute for the preferential uptake of HB-19 in lymphoid organs. Interestingly, HB-19 is preferentially taken up within lymphoid organs, which are the sites of HIV replication. Indeed, primary HIV infection is associated with a burst of viremia and wide dissemination and seeding of the virus to various organs, predominantly the lymphoid tissues that present a favorable environment for HIV replication (9, 19) . This acute phase of HIV infection is followed by a phase of ''clinical latency'' characterized by lack of symptoms that lasts for several years before the outburst of virus along the establishment of the acquired immunodeficiency syndrome. The fact that lymphoid tissues contain actively virus producing cells along latently infected lymphocytes suggests that they represent The two values in each column correspond to rat 1 and rat 2, respectively. Two rats were injected intravenously with [ 3 H]-labeled HB-19 (20 g; 1.8 MBq) and killed at 24 h. In order to estimate the presence of intact HB-19, the tissue extracts were assessed for RP-HPLC analysis (Materials and Methods). The total tritium activity was determined as counts per minute per gram of tissue. The % of total HB-19-associated tritium radioactivity within target organs represented the amount radioactivity quantified per organ in respect to the total radioactivity injected. The % of intact (undegraded) HB-19 in different tissues represented the amount of radioactivity quantified in the HB-19 HPLC peak with respect to the total radioactivity in each organ. At 45 min postinjection, tissue extracts were prepared as described in Materials and Methods. The HB-19 (A) or CP-51 (B) bound proteins were assayed by dot-immunoblotting using the antinucleolin polyclonal antibody. The HB-19 bound proteins were also analyzed by immunoblotting after SDS͞PAGE, using mAb D3 (C). A single band was identified by the antinucleolin antibody. C shows a section of the immunoblot (10% gel) at the region of the nucleolin migration (95 kDa).
